As a reminder, your coverage and/or enrollment selection for January 1, 2022 must be made online, or if mailed, must be received at the Funds lockbox by December 15, 2021.
For those who wish to enroll in the Medical Reimbursement Program (MRP) as a stand-alone option for 2022, you must provide proof that you have employer or union sponsored group health insurance that meets the minimum value standards of the Patient Protection and Affordable Care Act (ACA) and will cover you and/or your family in 2022.
If you have any questions or concerns, please email the Participant Services team at firstname.lastname@example.org.
The Winter 2021 Fund Office Newsletter is now available. Click here to read the latest newsletter which contains important information for all participants.
FUND-PROVIDED NO-COST COBRA COVERAGE JANUARY 1 to MARCH 31, 2022
CHANGE TO JANUARY 1 AND APRIL 1 REENTRY RULES
Please read this notice for more information.
Important Information Regarding the Plan C Medical Reimbursement Program (MRP)
If you are currently enrolled in the MRP Plan, as the 2022 Open Enrollment approaches, we want to remind you of important information regarding the Plan C - Medical Reimbursement Program (MRP). Please click here for more information on what you would be required to do to remain enrolled in the MRP Plan in the 2022 Plan year.
Click here to access helpful webinars presented by The Actors Fund
Empire BlueCross BlueShield*, CVS Health, Delta Dental, Davis Vision and MetLife have applications available for download for Android or IOS Mobile device platforms. Each application allows you to check claims, obtain I.D. Cards, search for a doctor or pharmacy in your location as well as other valuable tools to manage your health needs.
Click the link to each carrier flyer for more information on what each app can do and visit the Google Play store or the App Store to download each app.
* 8/2020 - Empire BlueCross BlueShield has a new app "Sydney" that will replace the “Empire Anywhere” application that you may currently be using.